Top 50 Medical Device Startup Investors in Asia (June 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Cowin Capital
VC Fund
|
13 | China, Hong Kong, United States | Series A, Series B, Seed | Manufacturing, Health Care, Biotechnology | $1.4M–$50M |
|
Qiming Venture Partners
VC Fund
|
13 | China, United States, Hong Kong | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $5M–$142M |
|
HSG
VC Fund
|
12 | China, United States, Hong Kong | Series A, Series B, Series C | Health Care, Biotechnology, Software | $4.4M–$214M |
|
BioVenture
VC Fund
|
11 | China, United States, Hong Kong | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $1.6M–$73M |
|
Shunwei Capital
VC Fund
|
11 | China, United States, India | Series A, Series B, Series C | Manufacturing, Software, Internet | $1.4M–$130M |
|
CD Capital
VC Fund
|
10 | China, United States | Series A, Series B, Seed | Health Care, Biotechnology, Medical Device | $1.4M–$34M |
|
Lilly Asia Ventures
VC Fund
|
10 | China, United States, Hong Kong | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $14M–$259M |
|
UntroD Capital
VC Fund
|
9 | Japan, Singapore, Austria | Seed, Series A | Manufacturing, Biotechnology, Medical | $2M–$241M |
|
BioTrack Capital
VC Fund
|
9 | China, United States, Singapore | Series A, Series B, Seed | Biotechnology, Health Care, Medical | $3M–$168M |
|
BIOCHING CAPITAL
VC Fund
|
9 | China | Angel, Series A, Seed | Medical Device, Medical, Biotechnology | $425k–$100M |
|
Haibang Capital
VC Fund
|
8 | China | Series A, Angel, Series B | Health Care, Biotechnology, Manufacturing | $425k–$71M |
|
IDG Capital
VC Fund
|
8 | China, United States, India | Series A, Series B, Series C | Software, Internet, E-Commerce | $3M–$190M |
|
Addor Capital
VC Fund
|
7 | China, Hong Kong, Singapore | Series A, Series B | Manufacturing, Semiconductor, Electronics | $1.4M–$43M |
|
Taiyu Investment
VC Fund
|
7 | China | Seed, Series A, Angel | Medical, Health Care, Biotechnology | $4.3M–$37M |
|
Prox Ventures
VC Fund
|
7 | China, United States, United Kingdom | Seed, Series A | Medical, Biotechnology, Health Care | $1.9M–$28M |
|
Jan Hammer
Angel
|
7 | China, United States, France | Series A, Series B, Seed | Health Care, Medical, Medical Device | $2.5M–$250M |
|
Dalton Venture
VC Fund
|
7 | China, India, Canada | Seed, Series A, Series B | Health Care, Medical, Biotechnology | $450k–$47M |
|
Med-Fine Capital
VC Fund
|
7 | China, Hong Kong, United States | Series A, Seed, Series B | Medical, Health Care, Biotechnology | $2.8M–$60M |
|
Legend Capital
VC Fund
|
7 | China, United States, South Korea | Series B, Series A, Series C | Health Care, Medical, Biotechnology | $2.8M–$200M |
|
EFung Capital
VC Fund
|
7 | China, United States, India | Series A, Series B, Series C | Health Care, Biotechnology, Medical | $1.4M–$130M |
|
Nippon Venture Capital
VC Fund
|
6 | Japan, United States | Series A, Series B | Software, Health Care, Medical | $3M–$425M |
|
Matrix Partners China
VC Fund
|
6 | China, United States, Hong Kong | Series A, Series B, Series C | Health Care, Biotechnology, Software | $2.8M–$200M |
|
Marathon Venture Partners
VC Fund
|
6 | China, United States, Hong Kong | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $1.4M–$462M |
|
CDH Investments
VC Fund
|
6 | China, United States, Canada | Series A, Series B, Series C | Manufacturing, Health Care, Biotechnology | $8.3M–$300M |
|
Oriza Seed Capital (Oriza Yuandian)
VC Fund
|
6 | China, United States, Singapore | Series A, Seed, Angel | Manufacturing, Health Care, Biotechnology | $213k–$90M |
|
Share Capital
VC Fund
|
6 | China, United States, Colombia | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $142k–$57M |
|
Sunland Fund
VC Fund
|
5 | China | Series B, Series A, Seed | Medical, Health Care, Medical Device | $1.4M–$28M |
|
JAFCO
VC Fund
|
5 | Japan, United States, Israel | Series A, Series B | Information Technology, Software, Artificial Intelligence | $2.7M–$425M |
|
Fast Track Initiative, Inc.
VC Fund
|
5 | Japan, United States, United Kingdom | Series A, Seed, Series B | Health Care, Biotechnology, Medical | $1.1M–$184M |
|
Goldport Capital
VC Fund
|
5 | China | Series A, Seed, Angel | Manufacturing, Medical, Semiconductor | $425k–$55M |
|
Mitsubishi UFJ Capital
VC Fund
|
5 | Japan, United States, Singapore | Series A, Series B | Information Technology, Software, Health Care | $2M–$397M |
|
Apricot Capital
VC Fund
|
5 | China, United States, Hong Kong | Series A, Seed, Series B | Biotechnology, Health Care, Medical | $3M–$58M |
|
Fortune Venture Capital
VC Fund
|
5 | China, Japan, United States | Series A, Series B, Seed | Manufacturing, Software, Information Technology | $425k–$73M |
|
SND Ventures Group
VC Fund
|
5 | China | Series A, Series B, Seed | Manufacturing, Semiconductor, Health Care | $709k–$90M |
|
SZHTI Group
VC Fund
|
5 | China, United States | Series A, Angel | Manufacturing, Electronics, Semiconductor | $425k–$14M |
|
Nissay Capital
VC Fund
|
5 | Japan, United States, Ethiopia | Seed, Series A | Health Care, Information Technology, Medical | $709k–$77M |
|
Oriza Holdings
VC Fund
|
5 | China, United States, Canada | Series A, Series B, Series C | Manufacturing, Health Care, Biotechnology | $1.7M–$200M |
|
UTEC - The University of Tokyo Edge Capital Partners
VC Fund
|
4 | Japan, United States, India | Seed, Series A | Health Care, Biotechnology, Medical | $3.1M–$85M |
|
UTokyo Innovation Platform
VC Fund
|
4 | Japan, United States, United Kingdom | Series A, Series B | Biotechnology, Medical, Manufacturing | |
|
Mizuho Capital
VC Fund
|
4 | Japan, United States, China | Series A, Series B | Information Technology, Software, Internet | $2.7M–$850M |
|
Green Pine Capital Partners
VC Fund
|
4 | China, United States, Canada | Series A, Series B, Angel | Biotechnology, Software, Manufacturing | $425k–$150M |
|
Huagai Capital
VC Fund
|
4 | China, United States, Germany | Series A, Series B, Angel | Health Care, Biotechnology, Medical | $425k–$90M |
|
ASBV
VC Fund
|
4 | China, Australia, Hong Kong | Seed, Series A, Angel | Health Care, Medical, Biotechnology | |
|
Keio Innovation Initiative
VC Fund
|
4 | Japan, United Kingdom | Series A, Seed | Health Care, Medical, Biotechnology | $1.5M–$400M |
|
Volcanics Venture
VC Fund
|
4 | China, United States, Hong Kong | Series A, Series B | Health Care, Artificial Intelligence, Biotechnology | $425k–$60M |
|
Frees Fund
VC Fund
|
4 | China, United States, Singapore | Series A, Seed, Angel | Artificial Intelligence, Health Care, Biotechnology | $425k–$35M |
|
HY Capital
VC Fund
|
4 | China, United States | Series A, Seed, Series B | Health Care, Medical, Medical Device | |
|
Seeds Capital
VC Fund
|
4 | Singapore, United States, Hong Kong | Seed, Series A, Series B | Software, Biotechnology, Health Care | $767k–$45M |
|
Highlight Capital
VC Fund
|
4 | China, United States, Portugal | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $2.8M–$84M |
|
Insight Capital
VC Fund
|
4 | China | Series A, Series B, Series C | Health Care, Medical, Biotechnology | |
| Access all 50 investors in Asia Medical Device startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Cowin Capital is a private placement equity investment company focusing on investing in a pioneering enterprise on a long-term basis. It has 18 years of experience in capital management, whose capital management scale was among the front rank, which invested more than 300 companies, of which 60 more became public companies, and 150 moresuccessfully exit.The company was successfully listed on NEEQ, with code 832793, as the third listed famous domestic venture capital institution in NEEQ. It is committed to supporting the growth of small and medium enterprises, continue to launch high-quality listed companies in China Capital Market.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 264
- Round size: Seed $1.4M–$20M; Series A $4.3M–$43M; Series B $2.8M–$50M
- Lead/follow: 45% lead, 55% follow
- Last fund: May invest from a new fund soon — raised $75M in 2014
Portfolio highlights
- HUAUN — HUAUN is a security vendor that focuses on vulnerability management and AI offense and defense.
- Sinsegye — Sinsegye operates as a product-driven enterprise company. Sinsegye is an industrial control supercomputing infrastructure supplier.
- Digital China — Digital China is a robotics company focused on developing humanoid interactive robots that can break traditional boundaries and create emotionally resonated partners.
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 716
- Round size: Series A $5M–$64M; Series B $10M–$100M; Series C $15M–$142M
- Lead/follow: 44% lead, 56% follow
- Last fund: Likely still investing — raised $887M in 2023
Portfolio highlights
- Fitlens — Fitlens
- Duet — Duet is a dating application helps you find meaningful relationships based on shared interests and experiences.
- Woof — Woof is a street fashion community and e-commerce platform for young generations.
We help founders build enduring companies.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Series B, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 751
- Round size: Series A $4.4M–$100M; Series B $12M–$200M; Series C $26M–$214M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- MarqVision — Effortlessly discover and remove counterfeits to protect your sales and reputation.
- Midas — Midas is the first neobroker of Turkey, providing zero commission Turkish and American stocks.
- Yunzhou Zhiwei — Yunzhou Zhiwei is a high-tech startup focused on serving large-scale equipment maintenance industries such as aviation, aerospace, shipbuilding, and rail transit. It leverages smart maintenance concepts and advanced digital technologies to make complex equipment maintenance more efficient and lean. The company drives industrial transformationtoward intelligent maintenance, helping enterprises enhance growth, efficiency, and operational excellence.
Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greaterdevelopment space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services.Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns.Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise.By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 151
- Round size: Seed $1.6M–$20M; Series A $1.9M–$42M; Series B $3M–$73M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- Dami&Xiaomi — Rice and millet is China's leading platform services for children with autism spectrum, from 2014 Nian 9 Yue Jiang Ying Shuang (rice) founded the "rice and millet" micro-channel public number. It now provides integrated services such as rehabilitation services, integrated education support, parent training, online courses, andpopular science information.
- CART Medical — CART Medical Technologies, Ltd. is a high-tech company specializing in the development and application of new technologies for immune cell therapy. It has a 2,200 square meter GMP laboratory and research and development laboratory.
- Ubiquitin Bio — Ubiquitin Bio is a research and development manufacturer of in vitro diagnostic products.
Shunwei Capital is a venture capital fund that focuses on early to mid-stage investments in local internet industry. It specializes in incubation, startups, early to mid-stage, and growth capital investments. It seeks to invest in the technology, media, telecommunications, high technology, new media, games, internet finance, and rural area internetsectors. Their investors include sovereign wealth funds, fund of funds, university endowment funds, and family offices.
Show more...Investment focus
- Industry: Manufacturing, Software, Internet
- Stage:Series A, Series B, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 408
- Round size: Series A $1.4M–$41M; Series B $8.2M–$50M; Series C $20M–$130M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $1.2B in 2018
Portfolio highlights
- CertiK — CertiK, the largest Web3 security service provider, uses AI and formal verification to protect and monitor smart contracts and protocols, securing the Web3 ecosystem.
- Darma — DARMA - Digital Healt
- LibLib AI — LibLib AI is an AI image generation platform that provides cutting-edge content creation through multi-scenario and multi-dimensional applications and interactions. It is a subsidiary of Beijing Singularity Star Technology Co., Ltd.
CD Capital is a venture capital firm specialized in life sciences and medical technology. They are currently managing both RMB and USD funds with total size of $600M. CD Capital is operated by a professional team with diversified and profound industry backgrounds. They have made over 40 investments with high growth potential and earned a reputationas a premier venture capital firm with main focus on China healthcare industry. With broad network around China and the world, they have been able to seize the global trend, capture investment opportunities as well as help to define the future for China healthcare industry. Ultimately, they strive to grow best-in-class companies and deliver solid financial return to their investors.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Series B, Seed
- Geography: China, United States
Investor stats
- Total investments: 67
- Round size: Seed $1.4M–$14M; Series A $1.4M–$27M; Series B $7.1M–$34M
- Lead/follow: 39% lead, 61% follow
Portfolio highlights
- Pipi Bear —
- Senas Medical — Senas Medical focuses on innovative cardiac electrophysiology solutions.
- Greenon Biotech — Greenon Biotech specializes in the research, development, production, and promotion of alternative antibiotic preparations for animals, which primarily include bacteriophages, probiotics, plant extracts, novel acid preparations, high-efficiency disinfectants, and so on.
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 209
- Round size: Series A $14M–$100M; Series B $25M–$112M; Series C $28M–$259M
- Lead/follow: 24% lead, 76% follow
- Last fund: May invest from a new fund soon — raised $40M in 2019
Portfolio highlights
- Passage Bio — Passage Bio, a genetic medicines company, is changing the future of CNS disorders and transforming the lives of patients and their families.
- Langlai Technology — Langlai Technology is a clinical-stage innovative drug research and development company. Adhering to the dual-drive strategy of synchronously improving the R&D pipeline and platform construction, it has built a full-process new drug R&D process from concept verification, candidate compound screening, preclinical druggability development toclinical research. system.
- Alebund Pharmaceuticals — Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.
UntroD Capital is an R&D-based innovative technology that specializes in social implementation.
Show more...Investment focus
- Industry: Manufacturing, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: Japan, Singapore, Austria
Investor stats
- Total investments: 119
- Round size: Seed $2M–$43M; Series A $2.1M–$241M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely actively investing — fund raised in 2024
Portfolio highlights
- CastBio — Castbio specializes in antibody-drug conjugate-based drug discovery research and development. Along with medications, it also creates research reagents, medical equipment, in vitro diagnostic items, and offers drug discovery consulting.
- Illumi Medical — Illumi Medical is a manufacturing company that produces medical equipment and devices for the healthcare sector.
- Reborna Biosciences — Reborna Biosciences provides research and development in the field of genetic diseases. The company develops therapeutic options for area of unmet medical needs in genetic rare disease. The company's technology enables low-molecular compounds to target ribonucleic acid. The company provides new disease-modifying drugs for patients sufferingfrom rare genetic diseases including spinal muscular atrophy.
BioTrack Capital invests in early and growth stage companies within life sciences, healthcare technology, biotechnology and related high-tech sectors, providing capital and investment support for innovation. The firm evaluates scientific and commercial potential of ventures and structures financings aimed at advancing technologies from earlyresearch to market engagement. Its activities include sourcing opportunities, conducting due diligence, and working with founders and management teams to align growth strategies with investor objectives. BioTrack Capital also participates in funding rounds alongside co-investors to support development of novel healthcare and tech solutions. The company engages with portfolio companies through strategic interaction and monitoring of progress toward business milestones.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 84
- Round size: Seed $14M–$168M; Series A $3M–$43M; Series B $14M–$150M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- PrinoPharma — PrinoPharma focuses on developing novel druggable sites targeting difficult-to-drug or existing druggable targets.
- Huihe Healthcare — Huihe Healthcare specializes in the development of medical devices for structural heart disease. The company was founded in 2019 and is headquartered in Shanghai, China.
- Rapafusyn Pharmaceuticals — Rapafuysn is pioneering RapaGlues - a modality of non-degrading molecular glues that addresses hard-to-drug targets.
BIOCHING CAPITAL is an investment management firm.
Show more...Investment focus
- Industry: Medical Device, Medical, Biotechnology
- Stage:Angel, Series A, Seed
- Geography: China
Investor stats
- Total investments: 20
- Round size: Angel $425k–$100M; Series A $14M–$14M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Lunke Medical — Lunke Medical focuses on the research, development, production, and sales of medical devices, with particular strength and expertise in high-pressure technologies. The company is committed to delivering safe, reliable, and innovative solutions by combining advanced engineering, strict quality control, and continuous technological advancement tomeet the evolving needs of the medical industry.
- Taose Tuantuan — Taose Tuantua is a sex toy company that primarily offers TAOSETT sex toy academy and exquisite sex toy community store services.
- Qinglan Jichuang — Qinglan Jichuang is a domestic high-performance intelligent endoscope innovative enterprise.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Zhejiang Haibang Investment Management Co., Ltd. (also referred as "Haibang Capital") is an investment company focusing on venture capital and private equity. It was established in 2011 in Hangzhou. It was founded by Naxin Yao, the CEO of Focused Photonics, Inc (300203), a number of returnee entrepreneurs and experienced investmentprofessionals. In 2011, Haibang Capital launched its first Haibang Fund (formerly called “Haibang Talent Fund”) which was the first venture capital in China helping new returnees to start their own businesses. It is also a fund connect capital and "Thousand Talent Program" in Zhejiang Province. Haibang Capital keeps working on helping enterprises grow rapidly and build leading edge in their industry. In addition to providing capitals, Haibang Capital provides its investee companies with personalized value-added services, helping create both good economic and social benefits.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Manufacturing
- Stage:Series A, Angel, Series B
- Geography: China
Investor stats
- Total investments: 40
- Round size: Angel $425k–$2.8M; Series A $1.4M–$14M; Series B $10M–$71M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- XPTC — XPTC is a wafer slicing equipment developer, dedicated to the research, development, production, and sales of ultra-precision thinning cutting equipment and related consumables.
- Wuwen Zhike — Wuwen Zhixing is an intelligent driving service provider dedicated to offering professional and cutting-edge integrated solutions for AI data and simulation verification, as well as developing AI data infrastructure and accelerators.
- Huashen Ruili — Huashen Ruili is a manufacturer and retailer of auto parts. It focuses on the advancement of drive motor systems' dry brake-by-wire technology.
IDG Capital is a global investment firm partnering with founders to build enduring businesses through capital, expertise, and long-term support.
Show more...Investment focus
- Industry: Software, Internet, E-Commerce
- Stage:Series A, Series B, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 705
- Round size: Series A $3M–$112M; Series B $7.4M–$142M; Series C $14M–$190M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- Polymaker — Polymaker is a high quality 3D printing filament manufacturers. PLA, PETG, ABS, ASA, TPU, Nylon, PC, Carbon Fiber and more. Find the best filament for your application.
- Ripple — Discover why hundreds of financial institutions choose Ripple to provide a better international payments experience for their customers in real-time.
- Singularity Energy Technology — Singularity Energy is committed to core technology research and product development in advanced energy storage systems, and contributes industry-leading solutions to promote large-scale clean energy integration and achieve global carbon neutrality goals.
Addor Capital offers investment services by financing early stage ventures and holding securities of other companies.
Show more...Investment focus
- Industry: Manufacturing, Semiconductor, Electronics
- Stage:Series A, Series B
- Geography: China, Hong Kong, Singapore
Investor stats
- Total investments: 270
- Round size: Series A $1.4M–$28M; Series B $11M–$43M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Heguang New Energy — Heguang New Energy is China's largest producer of square silicon cores for polysilicon and has long-term and stable purchase agreements with a number of major polysilicon producers.
- Matrix Software — Matrix Software is a research organization that focuses on the analysis, management, and prevention of information technology risks.
- Nanzhi Core Material — Nanzhi Core Material is a research and development manufacturer of optical grade lithium niobate crystal.
Taiyu Investment is an investment firm.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Seed, Series A, Angel
- Geography: China
Investor stats
- Total investments: 23
- Round size: Seed $4.3M–$7.4M; Series A $14M–$37M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- Immunocan — Immunocan focuses on the development of fully human antibody animals, artificial chromosome carriers with independent intellectual property rights, focusing on tumor treatment, and developing antibody therapeutic drugs.
- Rhino Medical — Rhino Medical develops advanced technologies with independent intellectual property rights. The founding team has rich experience in R&D, marketing, and clinical. On the basis of benchmarking imported phacoemulsification instruments and vitrectomy instruments
- Yili Pharmaceutical — Yili Pharmaceutical is a pharmaceutical R&D company that mainly engages in biochemical product technology R&D, medical research and experimental development, engineering and technology research and experimental development, and software development.
Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential.They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many yearsof remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.
Show more...Investment focus
- Industry: Medical, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: China, United States, United Kingdom
Investor stats
- Total investments: 72
- Round size: Seed $1.9M–$5.6M; Series A $2.8M–$28M
- Lead/follow: 15% lead, 85% follow
Portfolio highlights
- Brise Pharma — Brise Pharma operates in the scientific research and technical service industry.
- Tuanxiang Pharmaceutical — Tuanxiang Pharmaceutical is an innovative drug research and development company that combines traditional new drug research and development with the use of the world's leading unique phase separation technology.
- Rapafusyn Pharmaceuticals — Rapafuysn is pioneering RapaGlues - a modality of non-degrading molecular glues that addresses hard-to-drug targets.
Jan Hammer is the partner at Index and the Board observer of Harmonic. Jan attended Oxford University.
Show more...Investment focus
- Industry: Health Care, Medical, Medical Device
- Stage:Series A, Series B, Seed
- Geography: China, United States, France
Investor stats
- Total investments: 72
- Round size: Seed $2.5M–$15M; Series A $2.8M–$50M; Series B $14M–$250M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- Sofía — Improving the way millions of people take care of their health
- Transak — Transak offers a simple integration to allow your users to buy more than 100+ cryptocurrencies with credit/debit cards, or bank transfers in more than 120+ countries.
- Yuetong Eye Clinic — Yuetong Eye Clinic is a medical institution that provides myopia surgery for adults and myopia prevention and control for adolescents. It is a medical institution focusing on adult myopia surgery and adolescent myopia prevention and control.
Dalton Venture is a fund management company that specializes in early stage investment and industrial mergers and acquisitions in the field of big health.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: China, India, Canada
Investor stats
- Total investments: 129
- Round size: Seed $450k–$5M; Series A $2.8M–$17M; Series B $2.8M–$47M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- Aiyisheng —
- Bingjing Smart — Bingjing Smart is a cardiovascular interventional imaging company. It is an acoustics-based startup that uses imaging as a form of communication and is aiming for the digital medical revolution. It creates specialist digital interventional imaging products for heart and vascular illnesses. It helps in advancement of digital cardiovascularinterventional imaging, leveraging digital to empower the entire process of cardiovascular disease diagnosis and treatment.
- Rushen Robotics — Rushen Robotics focuses on the domains of rehabilitation and fitness, and is committed to building modular and human-machine integrated rehabilitation robots.
Med-Fine Capital is a venture capital firm focusing on early stage investments in China healthcare industry. The company is headquartered in Shanghai with offices in Beijing and Shenzhen.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 75
- Round size: Seed $8M–$21M; Series A $2.8M–$40M; Series B $11M–$60M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $69M in 2019
Portfolio highlights
- Zhuanma Biotech — Zhuanma Biotechnology is a gene editing service provider dedicated to clinically developing effective ultra-small gene editors into genetic therapeutics that are "curable once and for all."
- Excalipoint Therapetics — Excalipoint Therapeutics is a Private limited company.
- Beijing Ansong Technology — Beijing Ansong Technology Co., Ltd. is an enterprise focusing on the research and development, production, and sales of orthopedic medical devices. The company cooperates with domestic and foreign universities, research institutes, and doctors in hospitals, and is committed to creating original orthopedic products with independent knowledgeproducts.Beijing Ansong Technology was founded on June 27, 2011 by Liang Tao in Fengtai, Beijing.
Legend Capital, a subsidiary of Legend Holdings Ltd., started its vintage year in April, 2001 with a mission to become a top-notch and the most respected venture capital investment manager in China.Managing up to US$700 million across four funds, Legend Capital focuses on driving high-growth ventures with operations substantially based in Chinaor on markets related to China.Legend Capital mainly invests in early stage IT companies, specifically, in sectors of network applications and services, outsourcing and professional services, Infrastructure (IC design/key components), and mid-market growth stage companies in the fields of consumer goods, clean technology, health care, equipment manufacturing and modern services.Among over 60 portfolio companies are Joyo.com (acquired by Amazon.com), SinoCom (0299.HK), Solarfun Power (Nasdaq: SOLF), Spreadtrum Communications (Nasdaq: SPRD), China Sunshine Paper (2002.HK), and VanceInfo (NYSE:VIT), Eyang (0117.HK), etc.As an active investor, Legend Capital provides its portfolio companies extensive business resources and tailored services to assist with business development, company image building, and other critical company building activities on Chinese market so as to add value and maximize returns. Legend Capital is proud and thankful that it has the opportunity to blaze a trail with its innovative practice for China's venture capital industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series B, Series A, Series C
- Geography: China, United States, South Korea
Investor stats
- Total investments: 372
- Round size: Series A $2.8M–$94M; Series B $12M–$113M; Series C $14M–$200M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — raised $177M in 2021
Portfolio highlights
- Dipeak — Dipeak is a big data computing and artificial intelligence company that helps businesses traverse the AI era. Dipeak offers computer software services connected to data intelligence engines that integrate computing intelligence.
- Bespin Global — Bespin Global provides consulting, migration, managed services, and solutions for hybrid cloud. They rapidly implement architectures optimized for various industry areas into a hybrid cloud environment interacting with IDB using AWS, MS Azure, and Flexcloud. Bespin Global is a premium brand for strengthening Hostway's cloud business that hasprovided corporate professional hosting services and managed services since 1998 and is dedicated to Hostway's cloud managed service provider (MSP) business.
- Volant Aerotech — Volant Aerotech is a company specializing in the R&D, manufacturing, and service of passenger eVTOL, an electric vertical take-off and landing aircraft.
Shenzhen EFUNG Investment Management Enterprise L. P. is one of China's earliest institutions investing in professional biomedical industries. Their strong research team and great investment returns made us won 'The Most Pioneering VC Institution” 'The Most Dynamic Pharmaceutical VC Institution in China' and 'The Top Ten VCInstitutions in Shenzhen'. With this influence, EFUNG has drawn a lot of attention from the medical and life science industry. And it is interviewed by Nature, which is the most authoritative science magazine in the world. Over a decade of years, they have been focusing on the medical and health industry, especially the VC and PE investment business of novel drugs and high-end medical devices. The mission of EFUNG is to drive the industrialization of medical researches by capital and to gain rich returns to investors. EFUNG has deeply screened and invested in more than 20 domestic and international premium enterprises, such as Chipscreen Biosciences, Frontier Biotechnologies, Ascentage Pharma, Lifotronic, Aridis Pharmaceuticals, and Centrexion.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 63
- Round size: Series A $1.4M–$76M; Series B $14M–$113M; Series C $14M–$130M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Ruijiakang — Ruijiakang focuses on the research, development, and application of green synthetic biology production, as well as the layout and research of biofuels and biomaterials for non-grain anaerobic organic alkyd pipelines, and employs Zymomonas mobilis.
- Huiguan Biology — Huiguan Biology is a developer of super-resolution microscopes for in vivo drug screening.
- JGene Biotechnology — JGene Biotechnology is a research and development biotechnology company dedicated to the research and development of universal CAR-NK/T products from iPS. It is hoped that the large-scale production of CAR-NK/T from iPS will provide cancer patients with spot-type, price-friendly, and affordable new immune cell therapy products. Recentlyreceived angel round investment.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Nippon Venture Capital ("NVCC"), established in 1996 as one of the few largest Japanese independent venture capital firms, is destined to undertake the unprecedented task of providing full-range venture capital services in cooperation with major Japanese business leaders and leading companies, which have supported and nurtured various newbusinesses on their own, as well as proactively developing new venture enterprises.
Show more...Investment focus
- Industry: Software, Health Care, Medical
- Stage:Series A, Series B
- Geography: Japan, United States
Investor stats
- Total investments: 156
- Round size: Series A $3M–$85M; Series B $8.2M–$425M
- Lead/follow: 15% lead, 85% follow
- Last fund: Likely still investing — raised $278M in 2023
Portfolio highlights
- Surv Biopharma — Surv Biopharma develops a drug discovery platform that facilitates research and development of veterinary drugs and pharmaceutical products.
- Metagen Therapeutics — Metagen Therapeutics is a Drug discovery and medical business company which utilizes microbiome science.
- Restore Vision — Restore Vision is a startup based in Japan aiming to develop a visual restoration gene therapy.
Matrix Partners China builds long-term relationships with entrepreneurs and helps them build significant, industry-leading companies.Since its inception in 1977, Matrix Partners China has made hundreds of investments and played an active role in the development of many successful businesses, 50 of which went on to IPO, and 75 of which have goneon to profitable M&A events. The firm consistently ranks in the top venture firms in terms of returns to its investors.Matrix Partners China combines local knowledge with global experience and vision. Its team consists of both former entrepreneurs and experienced investors. Its past successes include Focus Media, Eachnet, and Baidu, among others. The company invests across multiple sectors and stages.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Series B, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 432
- Round size: Series A $2.8M–$60M; Series B $9.5M–$113M; Series C $14M–$200M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- Lexin — LexinFintech Holdings is an online consumer finance platform for educated young adults in China. As one of China's leading financial technology companies, Lexin integrates its e-commerce-driven installment finance platform, Fenqile, with advanced risk management technologies, the Company's Dingsheng online investment platform, and theCompany's Juzi Licai online investment platform for individual investors, to create a comprehensive consumer finance ecosystem. The Company utilizes technologies including big data, cloud computing and artificial intelligence to enable the near-instantaneous matching of user funding requests with offers from the Company's more than 30 funding partners, which include commercial banks, consumer finance companies, and other licensed financial institutions. By serving the credit needs of China's educated young adults, Lexin helps its more than 20 million registered users to enjoy a better quality of life through the use of better credit.
- Ouli Biomedical — Ouli Biomedical is a pharmaceutical company. They offer nucleic acid drug discovery, laboratory research and development, process and analysis development, CMC services, API production, and drug registration.
- Ucello Therapeutics — Ucello Therapeutics is engaged in development of allogeneic cell therapies using its proprietary CAR-T cell technology platform CBT-X20.
Marathon Venture Partners is an international VC fund that focuses on early and growth stage companies in healthcare and Fintech industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 63
- Round size: Seed $7M–$13M; Series A $1.4M–$28M; Series B $14M–$462M
- Lead/follow: 46% lead, 54% follow
Portfolio highlights
- Fungifuture — Fungifuture is a synthetic biomaterials company specializing in the research and development and production of fungal fiber materials.
- Ruize Health — Ruize Health is a commercial insurance company that focuses on health consumption and commercial insurance.
- Huamei Haolian — Huamei Haolian specializes in providing telemedicine and medical tourism services.
CDH Investments is an international alternative asset fund manager with over $27 billion of assets under management. CDH Investments was established in 2002 by the former private equity group of China International Capital Corporation and is managed by an experienced team of senior private equity professionals who have worked together for manyyears focusing all their professional time on investing in China. CDH has consistently delivered superior returns relative to industry peers and is well positioned to continue to generate superior returns due to the team's proven investment experience and expertise investing in China.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: China, United States, Canada
Investor stats
- Total investments: 261
- Round size: Series A $8.3M–$198M; Series B $14M–$142M; Series C $14M–$300M
- Lead/follow: 47% lead, 53% follow
Portfolio highlights
- ZSPepLib — Zonsen PepLib Biotech Inc. Zonsen PepLib Biotech Inc. is a high-tech biopharmaceutical enterprise that is dedicated to advancing global innovation in the discovery of new peptide drugs. Founded in September 2017, PepLib is headquartered in Zhuzhou, China, with a subsidiary in New Jersey, USA.
- Vision Medicals — Vision Medicals is a provider of pathogenic gene diagnostic services, focusing on infection-precise medical treatment, high-throughput sequencing-based pathogen metagenomics and CRISPR-based rapid diagnosis and other new technologies, effectively improving the detection ability of clinical pathogens and shortening The reporting cycle acceleratedthe development of the infection-accurate medical industry. The company developed a pathogenic nucleic acid enrichment technology with independent intellectual property rights for the detection of pathogenic micronucleic acids in clinical samples. The pathogen macro was established through the accumulation of pathogen detection big data. Genomics intelligent analysis and reporting system.
- Aibo Medical Robot — Aibo Medical Robot was established in Shenzhen in June 2020, focusing on the vascular interventional surgery robot market. It is reported that behind this "new" company is the accumulation of years of scientific research and technology - that is , the nearly 30 years of research and development accumulation of the founding team.
Oriza Seed Venture Capital, located in Suzhou Industrial Park, is held by Suzhou Oriza Holdings Ltd. Oriza Seed is a market-oriented investment platform. It looks for investment opportunities among early-stage and growth-stage enterprises in the fields of Healthcare and TMT. Oriza Seed has ample resources and experiences investing in the healthcarefield. By late March 2016, Oriza Seed has invested in more than 50 healthcare companies, including Ascentage Pharma, Innovent Biologics, and SceneRay Corporation.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Seed, Angel
- Geography: China, United States, Singapore
Investor stats
- Total investments: 128
- Round size: Seed $213k–$14M; Angel $425k–$2.1M; Series A $1.4M–$90M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Chuguang 3D — Chuguang 3D is a optical micro-nano 3D sensor technology platform that focuses on research and development, and manufacturing of micro-nano-level optical three-dimensional sensing and measurement and testing instruments.
- Null Hypothesis — Null Hypothesis is an AI medical SaaS company that focuses on the development of intelligent medical products using AIGC.
- Stairway Medical — Stairway Medical is a developer of implantable brain-computer interface technology.
Shanlan Capital is a professional fund focused on early and growing health care industry investments with offices in Shanghai and Beijing, focusing on biomedical and medical devices (in vitro diagnostics and gene technology, minimally invasive interventions, implantable devices, minimally invasive High-growth segments such as surgical instrumentsand medical robots, and medical services. It has invested in 15 medical star companies such as Guoke Hengtai, Ricky Surgery, Jingyi Medical, Haipulos, Langhe Medical, etc. The core team of Shanlan Capital is the founder of the medical industry listed company, professional financial and strategic investment. Composition of people, in strategy formulation, talent introduction, technology research and development, market camp..
Show more...Investment focus
- Industry: Medical, Health Care, Medical Device
- Stage:Series B, Series A, Seed
- Geography: China
Investor stats
- Total investments: 31
- Round size: Seed $1.4M–$14M; Series A $1.4M–$14M; Series B $2.8M–$28M
- Lead/follow: 45% lead, 55% follow
Portfolio highlights
- Aopeng Yiliao — Aopeng Yiliao is a developer of vascular interventional surgery robots.
- Bochuang Biotechnology — Bochuang Biotechnology is a cutting-edge medical repair product developer that specializes in the controllable electrochemical assembly of biomacromolecules. Bochuang Biotechnology is creating a line of high-end biological tissue functional membranes and derived medical device solutions.
- Yangshan Medical Technology — Yangshan Medical Technology is a Shanghai-based company specializing in dental surgery robots.
Since its founding in 1973, JAFCO has always worked with leading-edge entrepreneurs. The total capital commitments of its investment funds in Japan and overseas have exceeded 1 trillion yen and the number of portfolio IPOs to date has reached over 1,000. In addition to venture investment, JAFCO also carries out buyout investment and commit to thecreations of innovative technologies and services worldwide. As entrepreneurs’ closest partner in bringing their visions to life, JAFCO provides support in areas of HR, marketing/ sales, and back-office operations, in addition to providing financing.
Show more...Investment focus
- Industry: Information Technology, Software, Artificial Intelligence
- Stage:Series A, Series B
- Geography: Japan, United States, Israel
Investor stats
- Total investments: 252
- Round size: Series A $2.7M–$255M; Series B $8.3M–$425M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Caguuu — Caguuu offers high-quality designer furniture at affordable prices, through e-commerce, eliminating middlemen and store operating costs.
- QREATION — QREATION is a digital intellectual property studio specializing in producing a wide range of popular content that originates primarily from social media platforms. The company focuses on creating high-quality short-form entertainment, including short dramas, comedy sketches, and variety shows.
- ARCS — ARCS specializes in developing assisted reproductive medical devices using robotics and artificial intelligence technology.
Fast Track Initiative is a venture capital firm with an exclusive focus on life sciences and healthcare services.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Seed, Series B
- Geography: Japan, United States, United Kingdom
Investor stats
- Total investments: 73
- Round size: Seed $1.2M–$117M; Series A $1.1M–$142M; Series B $7.7M–$184M
- Lead/follow: 26% lead, 74% follow
- Last fund: May invest from a new fund soon — raised $1.1B in 2021
Portfolio highlights
- NovAccel — NovAccel operates as a deep tech company, ensure a stable supply of medical radioisotopes.
- Sonire Therapeutics — Sonire Therapeutics provides High-Intensity Focused Ultrasound treatment for cancer.
- Neusignal Therapeutics — Neusignal Therapeutics is a medical company that develops therapeutic medicines for dementia and psychiatric illnesses.
Goldport Capital is a Shenzhen-based asset management company.
Show more...Investment focus
- Industry: Manufacturing, Medical, Semiconductor
- Stage:Series A, Seed, Angel
- Geography: China
Investor stats
- Total investments: 60
- Round size: Seed $1.4M–$14M; Angel $425k–$14M; Series A $1.4M–$55M
- Lead/follow: 52% lead, 48% follow
Portfolio highlights
- Tianyuanxing — Tianyuanxing is a general industrial embodied intelligent platform developer whose primary focus is on the research and development of the "TX01" wheeled chassis humanoid dual-arm robot.
- Hangzhou Atom — Hangzhou Atom focuses on the R&D of atomic-level high-end materials manufacturing equipment, specializing in vacuum chemical vapor deposition
- Rongxin New Materials — Rongxin New Materials is a developer specializing in graphene material science and technology, with a commitment to the research and development of new materials technology and engineering applications. The company focuses on graphene-based heating films and graphene-integrated thermal products that are designed to provide efficient and uniformheating solutions for both consumer and industrial sectors.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Mitsubishi UFJ Capital is a venture capital firm focusing on life science, ICT, and high technology investments.
Show more...Investment focus
- Industry: Information Technology, Software, Health Care
- Stage:Series A, Series B
- Geography: Japan, United States, Singapore
Investor stats
- Total investments: 461
- Round size: Series A $2M–$113M; Series B $6.4M–$397M
- Lead/follow: 5% lead, 95% follow
- Last fund: May invest from a new fund soon — raised $1.4B in 2020
Portfolio highlights
- Taian — Taian, which specializes in bridal industry services and software. They also provide ''Concept Marry,'' which allows couples to design invites and seating charts that match their wedding theme, as well as display guest information on Oiwaii.
- Hydro Powtech Japan — Nippon Hydropowtech uses proprietary technology and experience in hydrolysate production to investigate new food applications.
- Mechano Cross — Mechano Cross is a mechanical company that offers mechanochemical organic synthesis technology for solution reactions.
Apricot Capital is an investment firm focused on investing in companies in the early and growing stages of the healthcare industry, including biopharmaceuticals, life sciences, medical devices, medical services, and diagnostics.Founded in 2015, Apricot Capital consists of more than 20 professionals and consultants with experience in thehealthcare industry. Its professional background includes life sciences, medicine, finance and law.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Series B
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 41
- Round size: Seed $10M–$28M; Series A $3M–$54M; Series B $14M–$58M
- Lead/follow: 46% lead, 54% follow
Portfolio highlights
- Vibrant — Vibrant develops an AI drug development platform to focus on building immune system-related drug pipelines. The company will use artificial intelligence algorithms to accelerate the efficiency of drug development in various aspects such as target discovery, drug design, and drug efficacy evaluation; at the same time, the company expects tocontinuously improve the success rate of drug development through sustainable data accumulation and algorithm optimization.It was founded and headed by Dr. Wang Luquan and is based in Guangzhou, Guangdong, China.
- Qihe Biotech — Qihe Biotech develops novel genome editing technologies with an emphasis on making them autonomous and programmable.
- LyncBio Therapeutics —
Fortune Capital, established in April, 2000, is one of the earliest market-oriented venture capital firms in China. For the past 14 years, Fortune Capital focus its investments on leading companies in four key sectors: TMT (Media oriented), Consumer Goods/Services, Modern Agriculture and Clean Tech.Fortune Capital is ranked among thehighest performing VC/PE firms in China and selected as "Vice President of Venture Capital Committee of IAC," "Vice President of Shenzhen VC Association," "Vice President of Shenzhen Chamber of International Investment & Funding," etc.In addition to providing capitals, Fortune Capital provides its investee companies with personalized value-added services.
Show more...Investment focus
- Industry: Manufacturing, Software, Information Technology
- Stage:Series A, Series B, Seed
- Geography: China, Japan, United States
Investor stats
- Total investments: 234
- Round size: Seed $425k–$73M; Series A $1.4M–$40M; Series B $2.8M–$56M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely still investing — raised $780M in 2021
Portfolio highlights
- Picea Motion — Picea Motion is a precision harmonic drive company that specializes in the development and production of harmonic speed reducers.
- Deep Robotics — Deep Robotics specializes in the application of the global quadruped robot industry. The founding team is rooted in Zhejiang University and has more than ten years of robotics research and development background. It is a high-tech company that attaches great importance to research and development and takes core technology as its maincompetitiveness. Sunshine has mastered the key core technology of quadruped robot motion control and has a number of independent and controllable intellectual property rights. The self-developed "Jueying" series of robots have reached the advanced level among similar products in the world and has been the first to be put into use in electric power, tunnel, fire protection, security, and other fields. Since its establishment in 2017, Yunshen has completed the R&D and sales layout of four series of products conducted multiple rounds of financing and built a complete organizational system. With the increasingly mature application of the quadruped robot industry, the company has entered a channel of rapid development.
- Tongli Haiyuan Biotechnology — Tongli Haiyuan Biotechnology focuses on the R&D and production of GMP-grade core raw material reagents for upstream cell and gene therapy.
SND Ventures Group is a venture capital and private equity firm specializing in seed investments.
Show more...Investment focus
- Industry: Manufacturing, Semiconductor, Health Care
- Stage:Series A, Series B, Seed
- Geography: China
Investor stats
- Total investments: 72
- Round size: Series A $1.4M–$43M; Series B $709k–$90M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Dezhi Matrix — Dezhi Matrix is focused on the larger semiconductor area, dedicated to constructing multimodal large-scale AI industrial models and delivering an AI-powered quality inspection solution.
- Sicui Thermal Control — Sicui Thermal Control focuses on the design of next-generation semiconductor and microelectronics thermal management solutions.
- Gongji Technology — Gongji is a technology-based company specializing in multi-source information fusion and positioning for intelligent vehicles.
SZHTI Group is a company that provides asset management and financing services.
Show more...Investment focus
- Industry: Manufacturing, Electronics, Semiconductor
- Stage:Series A, Angel
- Geography: China, United States
Investor stats
- Total investments: 117
- Round size: Angel $425k–$1.4M; Series A $780k–$14M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Elegoo — ELEGOO specializes in the research, development, and production of the most quality & affordable 3D printers, Arduino-based STEM & robotic kits, making technology easy-to-access for all the makers around the world.
- Junyi Technology — Shenzhen Junyi Technology Co., Ltd. is one of the world's leading OLED vapor deposition metal mask manufacturers. Its business includes OLED metal mask R&D, production and manufacturing, as well as supporting cleaning and maintenance services. Its customers cover CSOT, Truly Semiconductor, Royole Technology, Wuhan Tianma, BOE and otherdomestic OLED panel companies.
- Zhiqin Instruments — Zhiqin Instruments is an instrument supplier that offers full solutions for analysis and testing to important industries based on its own rapid detection mass spectrometer.
Nissay Capital is a venture capital Company specializing in seed, start-up, growth capital, middle stage, and later stage investment.
Show more...Investment focus
- Industry: Health Care, Information Technology, Medical
- Stage:Seed, Series A
- Geography: Japan, United States, Ethiopia
Investor stats
- Total investments: 223
- Round size: Seed $709k–$43M; Series A $2.7M–$77M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Todoker — Todoker is a baggage delivery convenient service providing company.
- CREO Bioscience — Cleo Bioscience is a Biotechnology company.
- Fabric Tokyo — FABRIC TOKYO is a Japanese startup provides a direct-to-consumer custom-made apparel brand. (former-company name Lifestyle Design Co., Ltd.). It enables customers to save their sizes, idea fabrics, and favorite designs, allowing them to make their original clothing later.FABRIC TOKYO was founded in 2012 by Yuichiro Mori and is based in Tokyo,Japan.
Oriza Holdings is a Chinese management fund that covers equity, debt financing, and investment since 2007.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: China, United States, Canada
Investor stats
- Total investments: 183
- Round size: Series A $1.7M–$43M; Series B $10M–$100M; Series C $14M–$200M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- TuringQ — Established in February 2021, TuringQ is committed to the research of quantum information. Through the R&D of lithium niobate on insulator (LNOI) photonic chips and femtosecond laser direct writing technology, the photon chips that enable large-scale photonic circuits integration can be prepared and an optical quantum system with a whole newlevel of scale and complexity can be built. At present, TuringQ has achieved leading advantages in photonic quantum chips, scientific research-grade photonic quantum computers, photonic quantum measurement and control systems, photonic quantum EDA software, and photonic quantum cloud platforms.
- Gazer — Gazer is a semiconductor equipment and sensor developer, focusing on the research and development, and innovation of sensing and control technology.
- Supermag — Suzhou Supermag Intelligent Technology Co., Ltd. (hereinafter referred to as Suci Technology) is committed to the research and development, production and sales of maglev high-speed motors. With the design authorization of magnetic levitation compressors, magnetic levitation blowers, magnetic levitation pumps, etc., it provides core components suchas magnetic levitation motors, magnetic levitation bearings, magnetic levitation controllers, and displacement sensors.
UTEC-The University of Tokyo Edge Capital Partners Co., Ltd.. UTEC is a seed/early stage technology focused venture capital firm associated with The University of Tokyo.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: Japan, United States, India
Investor stats
- Total investments: 172
- Round size: Seed $3.1M–$54M; Series A $5.2M–$85M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- ALGO ARTIS — ALGO ARTIS is a software company that offers optimization in plant operations, tanking, ship allocation plan, and logistics.
- SUN METALON — SUN METALON aims to create a world where metal products can be produced from local ores. The company was founded in 2021 and is headquartered in Redondo Beach, California.
- BUGWORKS Research — Bugworks, a clinical stage biopharmaceutical company Harnessing the power of science to develop affordable, accessible, novel therapies against infectious disea
The University of Tokyo IPC is a company responsible for expanding the innovation ecosystem of the University of Tokyo. Accelerate global innovation from the University of Tokyo through three activities: start-up support, investment business, and corporate innovation support.It was established as a wholly-owned subsidiary of the University ofTokyo in 2016 with the enforcement of the revised law of the Industrial Competitiveness Enhancement Law, which is the basis law. The investment targets of the Todai IPC are venture companies that utilize the research results and human resources of the University of Tokyo, but they also make FOF (fund of funds) investments in funds managed by some private venture capital companies. In 2019, it started a consortium-type incubation program (University of Tokyo IPC 1stRound) to support the establishment and financing of Tokyo University-related ventures.
Show more...Investment focus
- Industry: Biotechnology, Medical, Manufacturing
- Stage:Series A, Series B
- Geography: Japan, United States, United Kingdom
Investor stats
- Total investments: 65
- Lead/follow: no public data
Portfolio highlights
- Issin — Issin manufactures bath mats that can measure weight and automatically record daily weight changes on your smartphone.
- RoboTruck — RoboTruck develops autonomous driving technologies for huge trucks, as well as practical applications.
- Leading Mark — Leading Mark, a rising human resources startup in Japan. Leading Mark is branching out into mid-career and international hiring. It currently has a one-man team in China working to bring the top Japanese-speaking Chinese students to domestic companies. He also touts his startup’s focus on the average job seeker. “We want to make sure that the usersget the info that he or she needs the most,” he says. Large scale, legacy players can sometimes prioritize the needs of the hiring company, and their commission, over the needs of applicants themselves. This leads to frustration and short-circuited careers.
Mizuho is the venture capital firm affiliated to Mizuho Bank, the second-largest Japanese bank in terms of assets. The firm has headquarters in Tokyo.The firm has ¥49.6 billion JPY under management, focusing on information technology and biotechnology investments. Over 600 Mizuho companies have gone public. According to Nikkei, Mizuho is thefifth-largest venture capital firm in Japan.Mizuho Capital was formed in 2002 by the merger of Fujigin Capital, Tokyo Venture Capital and IBJ Investment. Three firms were subsidiaries of Fuji Bank, Dai-Ichi Kangyo Bank and the Industrial Bank of Japan respectively.
Show more...Investment focus
- Industry: Information Technology, Software, Internet
- Stage:Series A, Series B
- Geography: Japan, United States, China
Investor stats
- Total investments: 418
- Round size: Series A $2.7M–$156M; Series B $3.8M–$850M
- Lead/follow: 3% lead, 97% follow
- Last fund: May invest from a new fund soon — raised $1.4B in 2020
Portfolio highlights
- Logiless — Logiless is a cloud type all-in-one software dedicated to net shop. Since both orders and stocks can be managed together in a logical manner, efficiency of operations can be realized at low cost.
- ARCS — ARCS specializes in developing assisted reproductive medical devices using robotics and artificial intelligence technology.
- OpenHeart — OpenHeart is a provider of the tactile 3D platform.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Shenzhen Green Pine Capital Partners Co. Ltd. (“GPCP”) was established in 2007, with the investment team assembled in 2000. GPCP is one of the most time-honored Chinese VC companies that boast experience in areas such as biotech, new materials, new resources and AI, etc. Currently, GPCP manages assets over 15 billion RMB through 21 special fundsand have invested 7 billion RMB into 388 enterprises among which 14 are listed on NEEQ and 48 of them are either listed or acquired by listed companies, including BGI(300676.SZ), Aurora(600666.SH), Nationz Tech(300077.SZ), Foresee(002530.SZ), Qudian(NASDAQ:QD), etc. GPCP invested in the angel round of BGI (Beijing Genomics Institute), Royole, Kuang-Chi, Appotronics, BMF, C-one, Arrayed Materials and other star enterprises.GPCP is based in Shenzhen, with branches in Beijing, Shanghai and Guangzhou. GPCP also runs two GPI incubators and an incubator for overseas Chinese scientists who start businesses in China.
Show more...Investment focus
- Industry: Biotechnology, Software, Manufacturing
- Stage:Series A, Series B, Angel
- Geography: China, United States, Canada
Investor stats
- Total investments: 165
- Round size: Angel $425k–$2.9M; Series A $1.4M–$100M; Series B $4M–$150M
- Lead/follow: 30% lead, 70% follow
- Last fund: May invest from a new fund soon — raised $138M in 2019
Portfolio highlights
- MindRank AI — MindRank AI is a developer of proprietary end-to-end AI-driven drug discovery platform (Molecule Pro™).
- Ruitai Biotechnology — Ruitai is a developer for ophthalmic regenerative medicine, specialising in the R&D and sale of repair materials and medical device products
- Signet Therapeutics — Signet Therapeutics is a cutting-edge firm that conducts research and development on cancer-targeted drugs using AI and organoid disease models.
Huagai Capital is a private equity investment firm that invests in start-up or growth companies in the areas of healthcare, TMT, and culture.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Angel
- Geography: China, United States, Germany
Investor stats
- Total investments: 129
- Round size: Angel $425k–$15M; Series A $1.4M–$63M; Series B $3.5M–$90M
- Lead/follow: 42% lead, 58% follow
- Last fund: May invest from a new fund soon — raised $430M in 2018
Portfolio highlights
- PrinoPharma — PrinoPharma focuses on developing novel druggable sites targeting difficult-to-drug or existing druggable targets.
- Synaptic Medical — Synaptic Medical is a medical device company focused on the treatment of cardiac arrhythmias and other cardiovascular diseases.
- GenFleet Therapeutics — GenFleet Therapeutics is a developer and researcher of molecular pharmaceuticals targeting cancer treatments. The company specializes in developing innovative molecular-level pharmaceuticals and antibody drugs targeting various cancer systems, providing effective medical solutions to reactivate tumor-specific immune responses and to mobilize thebody's own immune system.
ASBV focuses on early and mid-term venture capital investments.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Seed, Series A, Angel
- Geography: China, Australia, Hong Kong
Investor stats
- Total investments: 27
- Lead/follow: no public data
Portfolio highlights
- Kaiyue Life — Kaiyue Life focuses on small molecule medication research & development for the treatment of human Ras mutant solid tumours.
- Boundary Intelligent Control — Boundary Intelligent is specialized in creating airborne systems, such as flight control systems, that satisfy the needs of civil aircraft, as well as enhancing the ecology of the civil aviation industry and constructing aircraft perception, navigation, decision-making, and planning capabilities.
- Longyue Mechanical and Electrical Technology — Longyue Mechanical and Electrical Technology engaged in technologies, strengthened linkages, and provided commercial aircraft services.
Keio Innovation Initiative (KII) is a venture capital established by Keio University. In order to make more effective use of the research results of Keio University, we aim to contribute to the development of society by creating investment for venture companies that utilize research results and creating new industries.The key to thinking aboutJapan's future growth strategy is to utilize advanced research results of the university. In addition to GDP, in addition to GDP, Japan is the world's third largest R & D exporter in R & D expenses, but as the low growth rate shows, it has a problem in investment efficiency in research and development. There are also reports on the entrepreneurial spirit that is indispensable for creating new industries, with the lowest entrepreneurial activity rate among developed countries.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Seed
- Geography: Japan, United Kingdom
Investor stats
- Total investments: 76
- Round size: Seed $1.5M–$213M; Series A $2.3M–$400M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — raised $1.4B in 2020
Portfolio highlights
- ElleThermo — elleThermo aims to implement Semiconductor-Sensitised Thermal Cells (STCs), an energy conversion technology that can generate electricity from unused waste heat above room temperature.
- Aeterlink — Aeterlink is a wireless device maker and developer. They applied their technology to fields such as FA, robots, smart houses, and medicine and developed practical level technologies such as elemental technology that can wirelessly supply power.
- Nanofiber Quantum Technologies — Discover how NanoQT builds the foundation for scalable quantum computing with nanofiber cavity-QED technology and high-fidelity quantum connectivity.
Volcanics Venture was founded in May 2016. They identify, invest in, and serve the most promising companies and outstanding entrepreneurs in Internet Innovation, Intelligent Technology and Healthcare industry. Managing Partners Suyang Zhang, Yeshun Dong and Ying Wu have been working closely for years as first-class USD/RMB fund managers.They have more than 60 years of aggregated VC investment and corporate management experience, as well as in-depth understanding of three focused fields. Volcanics Venture brings a powerful combination of global perspective and local experience to investment management, striving to provide sustainable value-added service to their portfolio companies and bring superior return to their limited partners.
Show more...Investment focus
- Industry: Health Care, Artificial Intelligence, Biotechnology
- Stage:Series A, Series B
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 102
- Round size: Series A $425k–$21M; Series B $5.7M–$60M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — raised $73M in 2018
Portfolio highlights
- Alluxio — Accelerate AI workloads, increase GPU utilization, and reduce infrastructure costs with Alluxio's AI-optimized, highly-distributed cache.
- Triastek — Triastek develops 3D printed medicines and the production facilities to manufacture them and has already filed patent applications for its technology.
- Vision Medicals — Vision Medicals is a provider of pathogenic gene diagnostic services, focusing on infection-precise medical treatment, high-throughput sequencing-based pathogen metagenomics and CRISPR-based rapid diagnosis and other new technologies, effectively improving the detection ability of clinical pathogens and shortening The reporting cycle acceleratedthe development of the infection-accurate medical industry. The company developed a pathogenic nucleic acid enrichment technology with independent intellectual property rights for the detection of pathogenic micronucleic acids in clinical samples. The pathogen macro was established through the accumulation of pathogen detection big data. Genomics intelligent analysis and reporting system.
By adopting revolutionary mechanisms, FREES FUND is devoted to change the long-established rules in the venture capital. By leveraging the cutting-edge technologies and resources, FREES FUND aims at investing in great startups and helping them grow into great enterprises that are valuable to our society. We mainly invest in early-stagestartups, and hope to become their first-round institutional investor. Our primary interested areas are broad-sense TMT (Technology, Media, Telecom), B2B and deep technology.
Show more...Investment focus
- Industry: Artificial Intelligence, Health Care, Biotechnology
- Stage:Series A, Seed, Angel
- Geography: China, United States, Singapore
Investor stats
- Total investments: 194
- Round size: Seed $1.4M–$14M; Angel $425k–$17M; Series A $1.4M–$35M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $130M in 2015
Portfolio highlights
- SoundAI — Sound Technology is a science and technology innovation company that specializes in acoustics frontier technology and artificial intelligence interaction. It is committed to lead the more interactive experience of artificial intelligence in the real environment and realize the human-computer interaction vision that "listen to you and know whatyou think".
- Jiajin Biotech — Jiajin Biotech is a pharmaceutical R&D service provider. It specializes in the development of antibody-small nucleic acid conjugates.
- Optical Standard Technology — Optical Standard Technology focuses on the design and manufacture of optical computing chips and optical computing boards for use in scenarios requiring large amounts of AI computing power, such as large model reasoning and training, autonomous driving, smart cities, quantitative finance, AI security.
HY Capital is a healthcare industry-focused investment firm that engages in early-stage investments, growth-stage investments.
Show more...Investment focus
- Industry: Health Care, Medical, Medical Device
- Stage:Series A, Seed, Series B
- Geography: China, United States
Investor stats
- Total investments: 20
- Lead/follow: no public data
Portfolio highlights
- Kang Ruijian — Kang Ruijian is a developer of thermosensitive modified chitin hydrogel technology.
- Onico Medical — Onico Medical is a medical device developer. The core team comes from the serious medical field and has absorbed professionals with rich experience in medical aesthetics development.
- Linyan Medical — Linyan Medical is a high-tech company focusing on the combination of man and machine in metaverse medical surgery.
Catalysing smart monies into Singapore-based, early-stage technology startups.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A, Series B
- Geography: Singapore, United States, Hong Kong
Investor stats
- Total investments: 121
- Round size: Seed $767k–$5.2M; Series A $3.5M–$24M; Series B $5M–$45M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- Datakrew — Datakrew delivers real-time EV battery analytics and AI-powered fleet intelligence. Smarter, safer fleets start here. Explore our solutions.
- Atomionics — Atomionics is building atomic sensors for navigation and resource exploration. Sensing technology is severely inadequate for a lot of applications navigation and positioning, pinpointing oil and gas reserves, tunnel detection etc. Atomionics builds atomic sensors harnessing quantum mechanical properties of the atoms. This enables measurement ofparameters like gravity, acceleration and rotation with 1000x higher precision and accuracy than the current state of the art, leading to a completely new way of global positioning, and resource exploration.
- Brano Therapeutics — Brano Therapeutics is a biotech developing therapies for cardio-metabolic and heart failure diseases.
Highlight Capital is an investment firm dedicated to support healthcare companies to generate robust and sustained growth prospect.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Portugal
Investor stats
- Total investments: 140
- Round size: Seed $8.5M–$84M; Series A $2.8M–$73M; Series B $7.6M–$70M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — raised $563M in 2021
Portfolio highlights
- Yixiu — Yixiu provides sleep health products such as smart wearables, smart home sleep scene hardware, sleep data analysis platforms, energy management apps, and more.
- Yushi Space — Yushi Space is a liquid rocket developer that focuses on the development and manufacture of large-capacity, low-cost and rapidly reusable liquid rockets.
- PoShell Robotics — PoShell Robotics is a general-purpose home robot, aiming to create a home-friendly and structurally stable robot.
Insight Capital is a venture capital firm focused on early-stage investment.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: China
Investor stats
- Total investments: 23
- Lead/follow: no public data
Portfolio highlights
- Sieran Medical — Sieran Medical is a medical device company that provides precise and intelligent minimally invasive surgical treatment solutions for ophthalmology.
- Amity Solutions — Enterprise Chatbots, AI-based generative Chatbots, pre-built social features for apps and websites, and building blocks for employee experiences.
- Iongen Therepeutics — Discovery of Novel Analgesics IonGen is a biotech company dedicated to the discovery of next-generation pain therapies without the addiction liabilities and side-effects associated with opioids.
FAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Medical Device Investors in Asia investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 48,091 investors investing in Asia Medical Device startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!